Genmab (GMAB) 43rd Annual J.P. Morgan Healthcare Conference summary

Strategic Vision and Evolution

• Aims to become a fully integrated biotech innovation powerhouse by 2030, focusing on transforming cancer and serious disease treatment through differentiated antibody therapeutics.

• Strong financials and recurring revenue from both wholly owned and partnered medicines, supported by over $2.6B in cash and a profitable, recurring revenue model.

• Acquisition of Profound Bio in 2024 expanded the oncology portfolio, adding Rina-S and additional ADC programs.

• Emphasis on a mix of internally developed and externally sourced assets, with a trend toward more 100% owned molecules and foundational investments in cost control.

• Partnerships remain integral for geographic expansion (e.g., China), technology innovation (including AI and digital), and advancing the pipeline.

Pipeline and Product Development Highlights

• EPKINLY (epcoritamab) is the first bispecific approved for both DLBCL and FL, with strong sales growth and five Phase 3 trials expected to expand its patient base by 2030.

• Tivdak (tisotumab vedotin) is the only ADC approved for cervical cancer, showing consistent sales growth and global expansion, including anticipated approval in Japan in 2025.

• Rina-S (rinatabart sesutecan), acquired via Profound Bio, is in phase III for ovarian cancer, with potential approval in 2027 and blockbuster sales anticipated; also in late-stage development for endometrial cancer.

• Acasunlimab (GEN1046), now wholly owned, shows promising phase II data in NSCLC and is advancing to phase III, targeting CPI-exposed patients and a billion-dollar market opportunity.

• Multiple proprietary and partnered assets are in clinical development, with seven active phase III trials and anticipated regulatory and data milestones in 2025.

Business Development and Financial Outlook

• Recurring revenue and profitability are driven by both own and royalty medicines, with significant growth projected through 2031.

• Royalty portfolio includes major products like DARZALEX, Kesimpta, TEPEZZA, TECVAYLI, TALVEY, and RYBREVANT, with combined sales expected to rise substantially by 2031.

• Operating expenses will grow in a focused manner, prioritizing late-stage clinical development and rigorous pipeline management.

• 2025 investment levels expected to align with analyst consensus (~$2.4 billion), with formal guidance to be provided in February.

• Strategic focus is on building a robust late-stage pipeline to offset future royalty expirations and sustain growth into the next decade.